Altoida awarded FDA breakthrough designation for development of world’s first precision neurology device for prediction of Alzheimer's disease

Altoida

5 August 2021 - Breakthrough designation will advance the development of industry’s first predictive diagnostic device for conversion to Alzheimer’s disease, backed by two decades of global clinical studies.

Altoida announced that their precision neurology device planned for use in Alzheimer’s disease and dementia diagnosis has been awarded breakthrough device designation by the U.S. FDA. 

The non-invasive software device which measures and monitors neurocognitive function is backed by two decades of global research, and is now being evaluated to predict conversion from mild cognitive impairment to Alzheimer’s disease with artificial intelligence.

Read Altoida press release

Michael Wonder

Posted by:

Michael Wonder